Executive Summary: Diabetes: Major World Markets, 3rd Ed. (Markets in US, Germany, Italy, Japan, Spain, UK and France)

Containing a snapshot of the overall market analysis, each Executive Summary provides a description of the scope and methodology used in the report; a summary of results including market size and market growth; a sampling of charts and graphs when available; and a brief look at the trends shaping the market.

The report from which this Executive Summary is compiled is Diabetes and Diabetic Complications: Major World Markets, 3rd Ed., and the full study abstract is as follows:

The market for diabetes-related products is huge and continuing to grow. However, it is not the same market as it was just 3 years ago. New trends in care, new products (both therapeutic and diagnostic), new approaches to long-term complications, and changing public health priorities and geographic variations are shifting the sands of opportunities in diabetes care.

This comprehensive re-evaluation of the major world market for diabetes monitoring and therapeutic products provides in-depth data and analysis including:

• Detailed epidemiology by country of Type I and II diabetes, with forecasts through 2016
• Market size and growth for each segment and subsegment in each country through 2016
• Thorough discussions of products on the market and evaluations of new products and technologies in development that may change the market of the future
• Considerations of the geographic market variations and very different diabetes care environments to be found in each of the major national markets.
• In-depth profiles of the top competitors and their diabetes-related portfolios
• 17 conclusions and strategic implications competitors in the marketplace must take into account as they formulate future plans

Market data (including size and growth projections) are provided for the major diagnostic and therapeutic segments:

• Glucose monitoring
• Insulin
• Oral hypoglycemics
• Antihypertensives for diabetes-related hypertension
• Lipid-lowering drugs for diabetes-related dyslipidemia
• Antiarrhythmics for diabetes-related arrhythmias
• Various drugs for diabetes-related peripheral vascular disease

• France
• Germany
• Italy
• Japan
• Spain
• United Kingdom
• United States